Analysts Set Icon Plc (NASDAQ:ICLR) Target Price at $203.81

Shares of Icon Plc (NASDAQ:ICLR) have been assigned an average rating of “Moderate Buy” from the twenty research firms that are presently covering the stock, MarketBeat reports. Twelve equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $199.8667.

Several research firms have issued reports on ICLR. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research note on Monday, December 29th. Bank of America lowered Icon from a “buy” rating to a “neutral” rating and set a $195.00 price objective for the company. in a research note on Monday, December 15th. Mizuho set a $216.00 target price on Icon in a research report on Friday, January 9th. Leerink Partners reaffirmed an “outperform” rating on shares of Icon in a report on Monday, January 5th. Finally, Cowen reiterated a “hold” rating on shares of Icon in a research report on Friday, October 24th.

Institutional Trading of Icon

Hedge funds and other institutional investors have recently bought and sold shares of the company. Private Trust Co. NA boosted its holdings in Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 94 shares during the period. Ameriflex Group Inc. bought a new stake in Icon in the third quarter valued at approximately $33,000. Ameritas Advisory Services LLC bought a new stake in Icon in the second quarter valued at approximately $48,000. LRI Investments LLC purchased a new stake in shares of Icon during the second quarter valued at approximately $49,000. Finally, Blue Trust Inc. grew its holdings in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after purchasing an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Stock Performance

Shares of ICLR stock opened at $184.77 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The firm has a market cap of $14.92 billion, a price-to-earnings ratio of 25.00, a P/E/G ratio of 3.86 and a beta of 1.26. Icon has a 52 week low of $125.10 and a 52 week high of $211.00. The firm’s 50-day simple moving average is $178.31 and its two-hundred day simple moving average is $173.69.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.